Schering-Plough/Merck Pharmaceuticals Submit NDA for Loratadine/Montelukast

Schering-Plough/Merck Pharmaceuticals, a joint venture between Schering-Plough and Merck, announced that the new drug application (NDA) for loratadine/montelukast has been accepted by the FDA.

Schering-Plough/Merck Pharmaceuticals said they are seeking U.S. marketing approval of loratadine/montelukast for treatment of allergic rhinitis symptoms.

The medicine is a single tablet that contains the active ingredients of Claritin (loratadine) and Singulair (montelukast sodium), both of which are indicated for the relief of symptoms of allergic rhinitis.